Trials / Completed
CompletedNCT03620474
Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis
Phase I / IIa Clinical Trial for Patients With Hepatitis C or B Virus Derived Liver Cirrhosis by CBP / β Catenin Inhibitor PRI-724
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Kiminori Kimura, MD · Academic / Other
- Sex
- All
- Age
- 20 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the safety and efficacy of PRI-724 against HCV or HBV liver cirrhosis.
Detailed description
【Phase I Phase】 To evaluate safety and pharmacokinetics when PRI-724 is administered to patients with HCV or HBV liver cirrhosis , and determine the recommended dose of PRI-724. 【Phase IIa phase】 To evaluate the efficacy and safety of the recommended dose of PRI-724 administered to patients with HCV or HBV liver cirrhosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PRI-724 | twice a week for 4 hours continuous intravenous administration of PRI-724 |
Timeline
- Start date
- 2018-07-24
- Primary completion
- 2021-07-13
- Completion
- 2022-02-28
- First posted
- 2018-08-08
- Last updated
- 2024-10-10
Locations
3 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03620474. Inclusion in this directory is not an endorsement.